SAR341402 vs THDB0206

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

SAR341402

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT03211858 · Phase 3 · completed

The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.

Reported efficacy

Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)

Result source: NCT03211858

THDB0206

Developed by Adocia and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05834868 · Phase 3 · completed

The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSAR341402THDB0206
HbA1c, change-0.4% vs -0.3%vs NovoLog/NovoRapidwk 26 · n 301NCT03211858
1 other result
  • -0.3% vs -0.3% wk 52 · n 301 · Phase 3 · secondary NCT03211858
—Not posted · NCT05834868
Body weight, change (kg)—Not reported—Not posted · NCT05834868
HbA1c below 7%19.6% vs 18.2%vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • 16.6% vs 14.5% wk 26 · n 301 · Phase 3 · secondary NCT03211858
—Not posted · NCT05834868
Fasting plasma glucose, change-0.1 vs -0.3vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • -0.5 vs -0.2 wk 26 · n 301 · Phase 3 · secondary NCT03211858
—Not posted · NCT05834868
3-point MACE (% with event)—Not reported—Not posted · NCT05834868

HbA1c, change

SAR341402
-0.4% vs -0.3%vs NovoLog/NovoRapidwk 26 · n 301NCT03211858
1 other result
  • -0.3% vs -0.3% wk 52 · n 301 · Phase 3 · secondary NCT03211858
THDB0206
—Not posted · NCT05834868

Body weight, change (kg)

SAR341402
—Not reported
THDB0206
—Not posted · NCT05834868

HbA1c below 7%

SAR341402
19.6% vs 18.2%vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • 16.6% vs 14.5% wk 26 · n 301 · Phase 3 · secondary NCT03211858
THDB0206
—Not posted · NCT05834868

Fasting plasma glucose, change

SAR341402
-0.1 vs -0.3vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • -0.5 vs -0.2 wk 26 · n 301 · Phase 3 · secondary NCT03211858
THDB0206
—Not posted · NCT05834868

3-point MACE (% with event)

SAR341402
—Not reported
THDB0206
—Not posted · NCT05834868
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

THDB0206: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. SAR341402: 4 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSAR341402
Dropout rate
12.3%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Discontinued due to AEs
2.7%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Serious AEs
12%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Most frequent reported AEs
nasopharyngitis 11.3%
upper respiratory tract infection 7.3%
influenza 5%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

SAR341402

HbA1c -0.38% (n=301) vs -0.3% (n=296) NovoLog/NovoRapid @ 26wk
absolute change · percentage points
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
-0.25% (n=301) vs -0.26% (n=296) NovoLog/NovoRapid @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
HbA1c Less Than 7% 16.6% (n=301) vs 14.5% (n=296) NovoLog/NovoRapid @ 26wk
responder rate · % of participants
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
19.6% (n=301) vs 18.2% (n=296) NovoLog/NovoRapid @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.49 vs -0.17 NovoLog/NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
-0.1 vs -0.34 NovoLog/NovoRapid mmol/L @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Daily Plasma Glucose -0.34 vs -0.53 NovoLog/NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
0.12 vs -0.18 NovoLog/NovoRapid mmol/L @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SAR341402's landscape · THDB0206's landscape